Melanotan II Dosage Guide: Tanning Protocol, Loading, and Side Effects

Melanotan II Dosage Guide: Tanning Protocol, Loading, and Side Effects

Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH), a naturally occurring peptide that regulates skin pigmentation. Originally developed at the University of Arizona in the 1980s during research into photoprotection, MT-II stimulates melanin production through MC1R, MC3R, MC4R, and MC5R receptor activation. Beyond tanning, the peptide has been studied for erectile dysfunction, libido enhancement, and appetite suppression.

This guide covers the evidence-informed dosing approach, administration method, cycle structure, and side effect profile of Melanotan II.

How Melanotan II Works

MT-II binds primarily to melanocortin receptors in the skin and brain. When it activates MC1R on melanocytes, it triggers increased production of eumelanin — the dark brown-black pigment — resulting in skin darkening even without UV exposure. The effect is amplified significantly with UV exposure, allowing users to tan faster and more deeply than without the peptide.

MC4R activation in the hypothalamus produces the libido-enhancing and appetite-suppressing effects, and is also responsible for some of the peptide's most notable side effects, including spontaneous erections in men and nausea.

Unlike alpha-MSH, which has a very short half-life, MT-II's cyclic structure makes it resistant to enzymatic degradation, extending its biological activity.

Starting Dose: The Low-and-Slow Approach

New users should begin at the lowest effective dose to assess tolerance before increasing. The most common initial dosing guideline is:

Week 1 sensitivity test:

• 0.25 mg subcutaneous injection once daily in the evening
• Administer 30–60 minutes before bed to sleep through initial nausea

Why evening dosing: The most common side effect of MT-II is nausea and flushing shortly after injection. Taking the dose before sleep allows most users to avoid experiencing the peak discomfort period.

If 0.25 mg is well tolerated after 3–5 days, the dose can be gradually increased.

Loading Phase Protocol

The loading phase builds up pigmentation. It typically runs 2–4 weeks depending on skin type and desired depth of tan.

Standard loading protocol:

• 0.25–0.5 mg subcutaneously once daily
• Combined with UV exposure (natural sunlight or tanning bed) 2–4 times per week
• Duration: 2–4 weeks or until desired tan depth is achieved

For UV-sensitive individuals or those prone to burning:

• Start at 0.1–0.25 mg to minimize flushing and nausea
• Allow pigmentation to build before increasing UV exposure

Fair-skinned individuals (Fitzpatrick skin types I–II) typically require longer loading phases and more UV sessions. Olive and darker skin types (types III–IV) often see faster results and may reach maintenance sooner.

Maintenance Dose

Once the desired level of pigmentation is achieved, the loading phase transitions into a maintenance protocol designed to sustain color with minimal dosing.

Standard maintenance protocol:

• 0.5 mg subcutaneous injection 1–2 times per week
• Continue periodic UV exposure to maintain and deepen color

Many users find they can maintain their tan on as little as one injection per week after the loading phase is complete. Some individuals with darker skin types can maintain pigmentation with even less frequent dosing.

The maintenance phase can continue indefinitely at the user's discretion, though most practitioners recommend taking breaks of several weeks between extended use periods.

Administration: Reconstitution and Injection

MT-II is supplied as a lyophilized (freeze-dried) powder in vials, typically 10 mg per vial. To prepare for injection:

1. Reconstitute with bacteriostatic water — 1–2 mL per vial depending on desired concentration
2. For a 1 mL reconstitution of a 10 mg vial: each 0.1 mL drawn = 1 mg; each 0.025 mL = 0.25 mg
3. Inject subcutaneously into the abdomen, outer thigh, or lower back fat — rotate sites
4. Use a 29–31 gauge insulin syringe, typically 0.5 inch needle length
5. Store reconstituted vials refrigerated; use within 30–60 days

Intranasal administration is used by some researchers, though bioavailability via this route is substantially lower and dosing is less predictable.

Side Effects and How to Manage Them

MT-II has a well-documented side effect profile, most of which are dose-dependent and diminish as the body adapts.

Common side effects:

• Nausea and vomiting — most frequent in the first 1–2 weeks; managed by evening dosing and starting at lower doses
• Flushing and warmth — facial flushing and warmth within 30–60 minutes of injection; usually subsides
• Spontaneous erections — due to MC4R activation; dose-dependent; less common at maintenance doses
• Appetite suppression — often a desired secondary effect; can contribute to lightheadedness if intake is not monitored
• Fatigue and yawning — particularly in the hour after injection; supports evening dosing timing

Less common side effects:

• Darkening of existing moles and freckles (existing pigmented lesions darken preferentially)
• New nevus formation (rare but reported)
• Blood pressure fluctuations

Mole monitoring: Because MT-II stimulates melanocytes non-selectively, it can darken existing moles and potentially alter their appearance. Users should conduct regular skin checks and consult a dermatologist before and during use, particularly those with a personal or family history of melanoma.

Stacking and Combination Protocols

MT-II is sometimes used alongside other peptides or agents to optimize results:

• PT-141 (Bremelanotide): A closely related melanocortin analog focused on sexual function without tanning; sometimes used alongside MT-II at lower doses
• BPC-157: For general peptide wellness stacks, though there is no direct synergy for tanning
• Vitamin D3 supplementation: Supports overall photoprotection and melanin metabolism during tanning protocols

Who Should Not Use Melanotan II

Melanotan II is a research chemical without regulatory approval for human use in most jurisdictions. Particular caution is warranted for:

• Individuals with a personal or family history of melanoma or other skin cancers
• Those with a high density of atypical moles
• People with a history of cardiovascular disease (due to transient blood pressure effects)
• Pregnant or breastfeeding women

Always consult a qualified healthcare provider before beginning any peptide protocol. For more general context on starting a peptide regimen, see our 30-day peptide challenge guide.

Frequently Asked Questions

Q: How long does it take to see tanning results with Melanotan II? Most users begin noticing pigmentation changes within 1–2 weeks of starting the loading protocol with regular UV exposure. Peak results typically appear after 3–4 weeks of consistent dosing and UV sessions.

Q: Can I use Melanotan II without UV exposure? MT-II can produce some degree of pigmentation without UV, but results are significantly slower and less pronounced. UV exposure dramatically amplifies the melanin response and reduces the total loading dose required.

Q: What is the difference between Melanotan I and Melanotan II? Melanotan I (afamelanotide) is a more selective MC1R agonist with a longer half-life, developed primarily for photoprotection in patients with erythropoietic protoporphyria. MT-II is non-selective across multiple melanocortin receptors, producing additional effects including libido enhancement. MT-I has fewer systemic side effects but is harder to source outside clinical settings.

Q: How should I store reconstituted Melanotan II? Reconstituted vials should be refrigerated at 2–8°C and protected from light. Most sources recommend using within 30–60 days once reconstituted. Unreconstituted powder stored in a freezer can last considerably longer.

Q: Will moles darken permanently? Darkening of moles during MT-II use is common and generally reversible after discontinuing the peptide, though some changes may persist. Any mole that changes shape, becomes irregular, or develops uneven borders should be evaluated by a dermatologist regardless of peptide use.